# INFORM (Galleri in people with inherited cancer risk)

Source: https://onco.cc/trials/inform-galleri/  
OnCo record `inform-galleri` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Dana-Farber study testing the Galleri blood test in people who carry an inherited gene change that raises their cancer risk.

## Summary

INFORM (NCT06450171) is a single-arm interventional study sponsored by Dana-Farber Cancer Institute. Its primary outcome is the cancer detection rate.

The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 1,000 participants, a start on 27 September 2024 and primary completion expected on 31 January 2027.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-29
- Also known as: INFORM study
- Registry id: NCT06450171
- Phase: not-applicable
- Setting: People with an inherited cancer predisposition at Dana-Farber Cancer Institute, screened with the Galleri test
- Sponsor: Dana-Farber Cancer Institute
- Enrolled: 1000

## Sources

- ClinicalTrials.gov NCT06450171: https://clinicaltrials.gov/study/NCT06450171

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- drugs: [Galleri](https://onco.cc/drugs/galleri/)
- companies: [GRAIL](https://onco.cc/companies/grail/)
- institutions: [Dana-Farber Brigham Cancer Center](https://onco.cc/institutions/dana-farber/)
- terms: [Hereditary cancer syndromes](https://onco.cc/terms/hereditary-cancer-syndromes/)

---
JSON: https://onco.cc/api/v1/entities/inform-galleri.json